8-K/A
Processa Pharmaceuticals, Inc. (PCSA)
View as plain text
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
(AmendmentNo. 1)
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Dateof Report (Date of earliest event reported): September 11, 2025
PROCESSA
PHARMACEUTICALS, INC.
(ExactName of Registrant as Specified in its Charter)
| Delaware | 001-39531 | 45-1539785 |
|---|---|---|
| (State or Other Jurisdiction<br><br> <br>of Incorporation) | (Commission<br><br> <br>File Number) | (IRS Employer<br><br> <br>Identification No.) |
| 601 21st Street, Suite 300 Vero Beach, FL | 32960 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’stelephone number, including area code: (772) 453-2899
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title<br> of each class | Trading<br> Symbol(s) | Name<br> of each exchange on which registered |
|---|---|---|
| Common<br> Stock, $0.0001 par value per share | PCSA | Nasdaq<br> Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
This Amendment No. 1 to the Current Report on Form 8-K amends the Form 8-K filed on September 12, 2025 (the “Original Form 8-K”) to add Item 5.03, Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year, as it relates to the approved Charter Proposal described in Item 5.07. No other changes have been made to the Original Form 8-K.
Item5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Effective September 12, 2025, Processa Pharmaceuticals, Inc. (the “Company” or “us” or “we”) filed an amendment to its Fourth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 100,000,000 shares to 1,000,000,000 shares (the “Amendment”). The Amendment was approved by the Company’s shareholders at a Special Meeting of Shareholders (the “Special Meeting”). The Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Item5.07 Submission of Matters to a Vote of Security Holders.
On September 11, 2025, the Company held the Special Meeting. A total of 50,349,149 shares of common stock were entitled to vote as of August 7, 2025, the record date for the Special Meeting. Present at the Special Meeting in person or by proxy were holders of 17,127,838 shares of common stock of the Company, representing at least one-third (1/3) of the voting power of the common stock of the Company outstanding and entitled to vote, constituting a quorum for the transaction of business.
The shareholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the shareholders and the final voting results of each such proposal.
| 1. | Approval<br> of an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized<br> shares of common stock from 100,000,000 shares to 1,000,000,000 (the “Charter Proposal”): | ||||
|---|---|---|---|---|---|
| Shares | |||||
| --- | --- | --- | --- | --- | --- |
| For | Against | Abstain | |||
| 13,706,276 | 3,029,091 | 392,471 | |||
| 2. | Approval<br> of an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation,<br> to effect a reverse stock split of the Company’s outstanding common stock, $0.0001 par value per share, at a ratio of not less<br> than 1-for-2 and not more than 1-for-50, such ratio to be determined in the sole discretion of the Company’s Board of Directors,<br> without a corresponding reduction in the Company’s authorized shares, and to be effective upon a date determined by the Board<br> of Directors no later than December 31, 2026 (the “Reverse Stock Split Proposal”): | ||||
| --- | --- | ||||
| Shares | |||||
| --- | --- | --- | --- | --- | --- |
| For | Against | Abstain | |||
| 13,887,533 | 3,126,720 | 113,585 | |||
| 3. | Approval<br> of an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive<br> Plan to increase the number of shares available for issuance under the Plan (the “OIP<br> Proposal”): | ||||
| --- | --- | ||||
| Shares | |||||
| --- | --- | --- | --- | --- | --- |
| For | Against | Abstain | |||
| 13,649,262 | 3,425,245 | 53,331 | |||
| 4. | Approval<br> of an adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if<br> there are insufficient votes in favor of the Charter Proposal, the Reverse Stock Split Proposal and/or the OIP Proposal or to establish<br> a quorum (the “Adjournment Proposal”): | ||||
| --- | --- | ||||
| Shares | |||||
| --- | --- | --- | --- | --- | --- |
| For | Against | Abstain | |||
| 14,039,730 | 2,563,581 | 524,527 |
Although the Adjournment Proposal was approved, the adjournment of the Special Meeting was not necessary because the shareholders approved the Charter Proposal, the Reverse Stock Split Proposal, and the OIP Proposal.
Item9.01(d) Financial Statements and Exhibits
| 3.1 | Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation |
|---|---|
| 104 | Cover<br> Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL documents) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROCESSA PHARMACEUTICALS, INC. | ||
|---|---|---|
| Date:<br> September 16, 2025 | By: | /s/ Russell Skibsted |
| Russell<br> Skibsted | ||
| Chief<br> Financial Officer |
Exhibit 3.1
Certificateof Amendment
tothe
fourthAMENDED AND RESTATED certificate of incorporation
of
Processapharmaceuticals, inc.
Processa Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows:
1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”).
2. The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the DGCL setting forth a proposed amendment to the Certificate of Incorporation and declaring said amendment to be advisable. The Certificate of Amendment amends the Certificate of Incorporation as follows:
The FOURTH paragraph of the Certificate of Incorporation is hereby deleted in its entirety and replaced with the following:
FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 1,000,000,000 shares of Common Stock, $0.0001 par value per share (“Common Stock”) and (ii) 1,000,000 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”).
The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.
A. COMMON STOCK
| 1. | General.<br> The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the<br> holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock<br> of any series. |
|---|---|
| 2. | Voting.<br> The holders of the Common Stock shall have voting rights at all meetings of stockholders, each such holder being entitled to one<br> vote for each share thereof held by such holder; provided, however, that, except as otherwise required by law, holders of Common<br> Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (which, as used herein, shall mean the<br> certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations<br> of any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders<br> of such affected series are entitled, either separately or together as a class with the holders of one or more other such series,<br> to vote thereon pursuant to this Certificate of Incorporation. There shall be no cumulative voting. |
| The<br> number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding)<br> by the affirmative vote of the holders of a majority of the stock of the Corporation entitled to vote, irrespective of the provisions<br> of Section 242(b)(2) of the General Corporation Law of the State of Delaware. | |
| 3. | Dividends.<br> Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board<br> of Directors and subject to any preferential dividend or other rights of any then outstanding Preferred Stock. |
| 4. | Liquidation.<br> Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled<br> to receive all assets of the Corporation available for distribution to its stockholders, subject to any preferential or other rights<br> of any then outstanding Preferred Stock. |
B. PREFERRED STOCK
Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the issue of such series adopted by the Board of Directors of the Corporation as hereinafter provided. Any shares of Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.
Authority is hereby expressly granted to the Board of Directors from time to time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series, by adopting, a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designations relating thereto in accordance with the General Corporation Law of the State of Delaware, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be stated and expressed in such resolutions, as to the full extent now or hereafter permitted by the General Corporation Law of the State of Delaware. Without limiting the generality of the foregoing, the resolutions providing for issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.
The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares then outstanding) by the affirmative vote of the holders of a majority of the voting power of the capital stock of the Corporation entitled to vote thereon, voting as a single class, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.
3. The requisite stockholders of the Corporation have duly approved this Certificate of Amendment in accordance with Section 242 of the DGCL.
4. This Certificate of Amendment shall be effective at 5:00 p.m. Eastern Time on September 12, 2025.
IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed as of the date set forth below.
| Dated:<br> September 12, 2025 | PROCESSA PHARMACEUTICALS, INC. | |
|---|---|---|
| By: | /s/ Russell Skibsted | |
| Name: | Russell<br> Skibsted | |
| Title: | Chief<br> Financial Officer |